KPMG: Reshape R&D to meet new needs
This article was originally published in Scrip
Executive Summary
Life sciences companies need to reshape R&D to provide reimbursable drugs and devices that deliver shareholder value and also become better at identifying who their customers are, what they want and how they want it delivered if they are to succeed in the new healthcare environment, according to a new report by the professional services consultancy, KPMG.